Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
Sandoz delivers another quarter of growth
Driven by Biopharma and ex-US sales
1
GROWTH
Growth rates
In cc
2%
8%
5%
4%
Q3 sales
% cc, USD bn
Europe
1.2
(+1%)
ROW
US
0.6
0.4
(+14%)
(-1%)
Maintaining
leadership
in Europe
Stabilizing
in US
Double-digit
growth Row
2021 2021 2022 2022 2022
Sales growth driven by biopharmaceuticals
-2%
Q3 Q4 Q1 Q2 Q3
Solid top line growth; 4th consecutive quarter
Russia/Ukraine impact offset by strong growth
in rest of Europe
Absorbing inflation, M&S investments tied to
sales growth
2022 FY guidance revised upwards
■ Sales: Grow low to mid SD (from low SD)
Core Oplnc: Grow low SD (from broadly in line)
Biosimilars main future growth driver
■
Targeting USD 80bn originator sales (2030) with
strong pipeline of 15+ biosimilar assets
■ FDA file acceptance for adalimumab HCF and
natalizumab
■ Positive Ph3 results for denosumab
Selectively pursuing small molecule opportunities
Novartis concluded that separation of Sandoz, via 100% spin-off, is in the best interests of shareholders; completion planned for H2 2023
HCF High concentration formulation
19 Investor Relations | Q3 2022 Results
U NOVARTIS | Reimagining MedicineView entire presentation